

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 May 2026

Comparison between efficacy of ciprofloxacin - Doxycycline and rifampin - Doxycycline regimens in treatment of brucellosis

Protocol summary

Summary

Background & objective : Brucellosis is one of the endemic diseases in Iran which has worldwide dissemination and is associated with chronic disabilities in humans. Combination therapy of brucellosis leads to recovery of symptoms, shortening of symptomatic interval and decrease in relapse rate and drug resistance. Considering the usage of rifampin in treatment of tuberculosis and necessity of an alternative treatment in regions in which both tuberculosis and brucellosis are endemic, in this study we compare the standard regimen of the WHO rifampin - Doxycycline with the regimen of ciprofloxacin - Doxycycline in treatment of brucellosis. Materials & Methods : This study is a RCT in which 90 patients with brucellosis who were elder than 17 years old and Negative inclusion criterial : pregnancy;age less than 17 years;endocarditis - meningitis ; spondylitis esophagitis ; consumption of ocp and phenynton; history of brucellosis (relapse) antimicrobial therapy for more than 7 day befor attending bad general condition attended between 1384-1387 in the Two clinics of infectious disease in Arak university of medical sciences were evaluated on the basis of Inclusion criteria's. The patients were randomly divided in two groups : Patients in DR groups, receiving Doxycycline 100 mg twice a day and rifampin 300 mg Bid daily for eight weeks, and the CD group , receiving Doxycycline 100 mg twice a day and ciprofloxacin 500 mg twice a day foot eight weeks. The patients were checked for the relief of symptoms , drug side effects and labratory findings during the treatment .patients evaluated for relapse , failure of treatment, drug side effects.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201103146056N1**

Registration date: **2012-03-10, 1390/12/20**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2012-03-10, 1390/12/20

Registrant information

Name

Nader Zarinfar

Name of organization / entity

Arak University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 86 1224 1411

Email address

zarinfar@arakmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Arak University of Medical Sciences

Expected recruitment start date

2006-02-09, 1384/11/20

Expected recruitment end date

2009-02-08, 1387/11/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison between efficacy of ciprofloxacin - Doxycycline and rifampin - Doxycycline regimens in treatment of brucellosis

Public title

Comparison between efficacy of ciprofloxacin - Doxycycline and rifampin - Doxycycline regimens in treatment of brucellosis

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria : patients with brucellosis in basis of clinical, epidemiological and serologic criteria, attended in the clinics of infectious disease in Arak university of medical sciences and age more than 17 years old.

Excusion criteria : pregnancy; age less than 17 years; endocarditis - meningitis ; spondy lities, esophagitis ; consumption of oral contraceptives or phenytion; history of brucellosis (relapse), antimicrobial therapy for more than 7 days befor attending; intolerance for oral medication and no desire for paticipating.

Age

From **17 years** old to **76 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **90**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Triple blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Aak University of Medical Sciences

Street address

Aak University of Medical Sciences, Alamalhoda ave.

City

Arak

Postal code

Approval date

2006-02-06, 1384/11/17

Ethics committee reference number

88-83-7/1

Health conditions studied

1

Description of health condition studied

Brucellosis

ICD-10 code

A23.0

ICD-10 code description

Brucellosis due to Brucella melitensis

Primary outcomes

1

Description

Clinical improvement

Timepoint

At the beginning of the study - second & third & and nine months serologic test in second & sixth& mounths

Method of measurement

Patients' history and physical exam and serologic results(clinical , wrigth , 2ME , serologic)

Secondary outcomes

1

Description

Relapse

Timepoint

Sixth & ninth mounths from the begining of the study

Method of measurement

Clinical improvment and serology

2

Description

Failure of the treatment

Timepoint

Three mounth

Method of measurement

Clinical improvment and serology

3

Description

Drug side effects

Timepoint

During the treatment

Method of measurement

Clinical assessment

Intervention groups

1

Description

In case group : ciprofloxacin 500mg twice aday and doycycline 100mg twice a day for two months

Category

Treatment - Drugs

2

Description

In control group Rifampicin 300mg BID & Doxycyclin 100mg BID for two months

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Valieasr hospital

Full name of responsible person

Assistant professor Arak university of medical sciences, Infectious disease specialist

Street address

valieasr hospital Arak

City

Arak

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr. Davood hekmatpoor

Street address

Arak Meydan basij

City

Arak

Grant name

31004

Grant code / Reference number

1107

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Arak University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr. Farshideh Didgar

Position

Infectious disease specialist

Other areas of specialty/work

Street address

Arak - Valieasr hospital-

City

Arak

Postal code

3814957558

Phone

+98 86 1224 1411

Fax

+98 86 1224 1411

Email

dr.didgar@arakmu.ac.ir

Web page address

arakmu.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr. Farshideh Didgar

Position

Infectious disease specialist

Other areas of specialty/work

Street address

Arak Valieasr hospital

City

Arak

Postal code

3814957558

Phone

+98 86 1224 1411

Fax

+98 86 1224 1411

Email

zarinfar@arakmu.ac.ir; didgar@yahoo.com

Web page address

arakmu.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr. Farshideh Didgar

Position

Infectious disease specialist

Other areas of specialty/work

Street address

Arak Valieasr hospital

City

Arak

Postal code

3814957558

Phone

+98 86 1224 1411

Fax

+98 86 1224 1411

Email

zarinfar@arakmu.ac.irfdidgar@yaho.com

Web page address

arakmu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty